Genetics and treatment of actinic prurigo in Thailand
Part of Skin clinical trials.
This study looks at the genetics of actinic prurigo (a sun-sensitive rash) and how thalidomide affects it. It may help find better treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be of Thai ethnicity.
- You must have been diagnosed with actinic prurigo (a sun-triggered rash) by the study's criteria.
- You must be mentally able to understand and follow the study instructions in Thai.
- If you take thalidomide, you must use two types of birth control (like pills and condoms) starting 4 weeks before and continuing during and 4 weeks after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how a new drug works in people with actinic keratosis (rough, scaly patches caused by sun damage) on their upper arms or face. You will receive the treatment and have blood samples taken to see how your body processes the medication.
This study tests an investigational drug called HW211026 on actinic keratosis — rough, sun-damaged patches on the face. The goal is to see if this treatment can safely clear them up.
This trial tests an experimental drug called ICP-332 for people with prurigo nodularis (a condition causing very itchy, hard bumps on the skin). It aims to see if the drug can safely reduce itching and improve skin lesions.
This study tests an experimental medication (ACT-777991) taken by mouth to see if it can help repigment skin in adults with non-segmental vitiligo. It aims to learn how safe it is and how well it works.
This study tests an oral medication called erlotinib (an EGFR inhibitor) to see if it can reduce the skin symptoms of keratinopathies like epidermolytic ichthyosis, epidermolytic palmoplantar keratoderma, and pachyonychia congenita. The goal is to improve skin condition and quality of life.
This trial tests a new medicine called TEV-53408 to see if it can help with vitiligo, a condition that causes white patches on the skin. It may help by restoring skin color, and the study will check how safe and effective it is.
Hear when a new Actinic Prurigo trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.